• Vivos Therapeutics filed a Form 3 showing V-Co Investors 4 LLC as a 10% owner, triggered by an event dated June 30, 2026.
• V-Co reported direct beneficial ownership of Series A Convertible Preferred Stock convertible into 2,749,330 common shares at an exercise price of $0.46.
• The filing also lists a common stock purchase warrant exercisable June 30, 2026, expiring June 30, 2031, covering 2,749,330 shares at $0.46.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-304807), on July 15, 2026, and is solely responsible for the information contained therein.